Our Team in the News

BioPlan Associates' Ronald Rader

Ron Rader, Sr. Dir. Technical Research: named Editor-in-Chief of Biopharmaceuticals a new peer-reviewed journal from Landes Bioscience. Biopharmaceuticals is the first and only peer-reviewed journal about biopharmaceuticals. Biopharmaceuticals seeks submission of articles concerning biopharmaceuticals and the industry. Please contact the Editor-in-Chief if interested in submitting an article.

BioPlan Associates' Faiz Kermani PhD

Dr Faiz Kermani, Advisory Board: Has helped establish the "Global Health Education Foundation" (GHEF), a not-for-profit healthcare charity to improve educational resources and training for healthcare professionals in developing countries.
At least 1.3 billion people worldwide lack access to the most basic healthcare. The new non-profit foundation, Global Health Education Foundation, aims to tackle such issues. As President of GHEF, Dr Kermani is supporting the R&D focus of the charity to reduce health disparities among developing countries. In particular, the lack of appropriate educational resources and training opportunities for healthcare professionals. http://www.globalhef.org

BioPlan Associates' Managing Director Eric Langer

Eric Langer, Managing Partner: On Advisory Board of “BioProcess Asia Pacific Conference” July 2010 Singapore.
The Biopharmaceutical market in Asia pacific is growing at a rate among the highest in the globe. This is creating a strong need for production of biopharmaceuticals at higher qualities and volumes. Bioprocess AsiaPacific brings together global leaders within biopharmaceutical industry to explore dynamic strategies, benchmark technologies and analyze sustaining the growth of the industry. http://fleminggulf.com/conference/life-science/BioProcessAsiaPacific.

Publications, Reports and Books

8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production

The 2012 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production. This year's 9th Annual Report and Survey of Biopharmaceutical Manufacturing shows the industry has returned to robust growth. Based on analysis of 302 global biomanufacturers' 2012 budgets, expect substantial investment in new technologies that:

  • Reduce costs and improve productivity
  • Focus on novel downstream technologies
  • Improve single-use device adoption rates

This year, among the hundreds of significant findings: Budgets are growing in all areas measured, but the great majority are continuing to actively implement cost-cutting initiatives; a broad range of new products are being demanded from industry vendors to solve productivity problems, especially in single use and chromatography areas.

Published by BioPlan Associates, Inc. May 2012
ISBN 978-1-934106-22-8

Download Brochure 972k

Download Table of Contents 1.5MB

Hardcover Digital Global License
Order Now Order Now

  • Coverage
  • Table of Contents
  • By the Numbers

This report's 471 pages of data-rich analysis will help improve your decision-making in biomanufacturing operations, with in-depth analysis of capacity, production trends, benchmarks, and much more:

  • Biosimilars pipeline in development
  • In-depth analysis of key data, capacity, production trends, and benchmarks
  • Budget trends and impact of current economic environment
  • Expression system advances
  • Downstream purification problems and issues
  • Current and projected industry bottlenecks
  • Capacity utilization and current production levels
  • How capacity bottlenecks are being resolved
  • Production trends and implications for industry
  • Outsourcing trends
  • International offshoring through 2017
  • Range of titres, growth
  • Disposables: Spending growth; downstream uses; L&E's; reasons for increasing/ restricting; budget increases; vendor satisfaction
  • Disposables: Compare innovators vs CMOs & US vs Europe
  • Batch failure rates & trends
  • Selecting a CMO — Problems & solutions
  • Quality management & PAT implementation
  • Hiring and employment growth
  • Supplier growth rates
  • Much more...

Compare 302 biotherapeutic developers vs CMOs; US vs European & Global Biomanufacturing

  • Overview
  • Methodology
  • CHAPTER 1: Introduction and Discusssion
  • CHAPTER 2: Demographics
  • CHAPTER 3: Emerging Issues: Budgets, Expression Systems, Operational Changes
  • CHAPTER 4: Capacity Utilization
  • CHAPTER 5: Current Capacity Constraints
  • CHAPTER 6: Future Capacity Expansions
  • CHAPTER 7: Outsourcing Trends in Biopharmaceutical Manufacturing
  • CHAPTER 8: Disposables and Single-Use Systems in Biopharmaceutical Manufacturing
  • CHAPTER 9: Downstream Purification
  • CHAPTER 10: Quality Issues, Batch Failures, and PAT in Biopharmaceutical Manufacturing
  • CHAPTER 11: Hiring, Employment Growth, Training
  • CHAPTER 12: Suppliers to Biopharmaceutical Manufacturing

    • Download the complete Table of Contents 1.5MB

  • 302 Biomanufacturers and CMOs surveyed
  • 185 Direct industry suppliers
  • 29 Countries represented
  • 471 Pages
  • 12 Chapters
  • 208 Graphs and 21 tables
  • 12 Subject Matter Experts providing analysis
  • 22 Independent Sponsoring Organizations